<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767802</url>
  </required_header>
  <id_info>
    <org_study_id>PTG-300-08</org_study_id>
    <nct_id>NCT04767802</nct_id>
  </id_info>
  <brief_title>PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit</brief_title>
  <official_title>A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protagonist Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protagonist Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm trial of PTG-300 in subjects with PV who are newly&#xD;
      diagnosed or for whom current therapy is not sufficient to control their hematocrit and have&#xD;
      hematocrit &gt;48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4&#xD;
      weeks to maintain hematocrit &lt;45% with a target of &lt;43%. Subjects may receive PTG-300&#xD;
      treatment for up to 52 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate PTG-300's efficacy in subjects with PV and baseline elevated hematocrit.</measure>
    <time_frame>Estimate the proportion of subject with a hematocrit less than 45% at Week 16</time_frame>
    <description>Proportion of subjects with hematocrit &lt;45%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of PTG-300</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of Subjects Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>PTG-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTG-300</intervention_name>
    <description>Hepcidin mimetic</description>
    <arm_group_label>PTG-300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Known diagnosis of polycythemia vera.&#xD;
&#xD;
          2. Hematocrit &gt;48% before dosing.&#xD;
&#xD;
          3. Evidence of hematocrit &gt;48% three or more times in the 28 weeks before dosing or five&#xD;
             or more times in 52 weeks before dosing (except for newly diagnosed patients).&#xD;
&#xD;
          4. Clinically reasonable alternative causes for erythrocytosis have been evaluated and&#xD;
             excluded.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein&#xD;
             thrombosis) within 3 months of Screening.&#xD;
&#xD;
          2. Active or chronic bleeding within 4 weeks of Screening.&#xD;
&#xD;
          3. Meets the criteria for post-PV myelofibrosis as defined by the International Working&#xD;
             Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).&#xD;
&#xD;
          4. Infection requiring hospitalization or intravenous antimicrobial therapy, or&#xD;
             opportunistic infection within 3 months of dosing; any infection requiring systemic&#xD;
             antimicrobial therapy within 4 weeks of dosing. Prophylactic antibiotics are allowed.&#xD;
&#xD;
          5. Any serious or unstable medical or psychiatric condition that would prevent, (as&#xD;
             judged by the Investigator) the subject from properly providing informed consent or&#xD;
             any condition which would jeopardize compliance with the study.&#xD;
&#xD;
          6. Known primary or secondary immunodeficiency.&#xD;
&#xD;
          7. Known positive for active hepatitis B, hepatitis C or human immunodeficiency virus&#xD;
             (HIV) infection.&#xD;
&#xD;
          8. Any surgical procedure requiring general anesthesia within 1 month prior to Screening&#xD;
             or planned elective surgery during the study.&#xD;
&#xD;
          9. History of invasive malignancies within the last 2 years, except non-melanoma skin&#xD;
             cancer and localized curatively treated prostate cancer or cervical cancer.&#xD;
&#xD;
         10. Current or recent history of alcohol dependence or illicit drug use within 1 year&#xD;
             prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gachon University Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Catholic University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab</name>
      <address>
        <city>Kota Bharu</city>
        <state>Kelantan</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Permaisuki Bainun</name>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

